NEW YORK (TheStreet) -- JP Morgan initiated coverage on Jazz Pharmaceuticals (JAZZ) with an "overweight" rating and a $190 price target. The firm said the company is well positioned for organic growth or the possibility of an acquisition.
The stock was up 2.28% to $155.98 in pre-market trading on Tuesday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.